Is Pfizer Inc. a good investment? Pfizer Inc. (PFE.MX) is currently trading at 474.13 MXN.
In terms of valuation, the stock trades at a P/E ratio of 37.30. This high multiple suggests investors have priced in significant future growth expectations.
For income investors, Pfizer Inc. pays a dividend yield of 6.28%. With a payout ratio of 226%, the dividend appears to be under pressure.
Yes, it pays an annual dividend of 30.13 MXN (6.28% yield).
Pfizer Inc. is classified as a Stock. You can compare it against 12 other assets in the "Related Symbols" list on this page.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
| Year | Total Dividends |
|---|---|
| ▸2027 |
22.44 MXN
|
| July 23, 2027 (estimated) | 7.4798 |
| May 28, 2027 (estimated) | 7.4798 |
| Jan. 22, 2027 (estimated) | 7.4798 |
| ▸2026 |
29.36 MXN
|
| Nov. 27, 2026 (estimated) | 7.4798 |
| July 24, 2026 | 7.2950 |
| May 8, 2026 | 7.2950 |
| Jan. 23, 2026 | 7.2950 |
| ▸2025 |
29.18 MXN
|
| Nov. 7, 2025 | 7.2950 |
| July 25, 2025 | 7.2950 |
| May 9, 2025 | 7.2950 |
| Jan. 24, 2025 | 7.2950 |
| ▸2024 |
28.50 MXN
|
| Nov. 8, 2024 | 7.1253 |
| July 26, 2024 | 7.1253 |
| May 9, 2024 | 7.1253 |
| Jan. 25, 2024 | 7.1253 |
| ▸2023 |
27.82 MXN
|
| Nov. 9, 2023 | 6.9557 |
| July 27, 2023 | 6.9557 |
| May 11, 2023 | 6.9557 |
| Jan. 26, 2023 | 6.9557 |
| ▸2022 |
27.14 MXN
|
| Nov. 3, 2022 | 6.7860 |
| July 28, 2022 | 6.7860 |
| May 12, 2022 | 6.7860 |
| Jan. 27, 2022 | 6.7860 |
| ▸2021 |
26.47 MXN
|
| Nov. 4, 2021 | 6.6164 |
| July 29, 2021 | 6.6164 |
| May 6, 2021 | 6.6164 |
| Jan. 28, 2021 | 6.6164 |
| ▸2020 |
25.79 MXN
|
| Nov. 5, 2020 | 6.4467 |
| July 30, 2020 | 6.4467 |
| May 7, 2020 | 6.4467 |
| Jan. 30, 2020 | 6.4467 |
| ▸2019 |
24.43 MXN
|
| Nov. 7, 2019 | 6.1074 |
| Aug. 1, 2019 | 6.1074 |
| May 9, 2019 | 6.1074 |
| Jan. 31, 2019 | 6.1074 |
| ▸2018 |
23.07 MXN
|
| Nov. 8, 2018 | 5.7681 |
| Aug. 2, 2018 | 5.7681 |
| May 10, 2018 | 5.7681 |
| Feb. 1, 2018 | 5.7681 |
| ▸2017 |
16.29 MXN
|
| Aug. 2, 2017 | 5.4288 |
| May 10, 2017 | 5.4288 |
| Feb. 1, 2017 | 5.4288 |
| ▸2016 |
20.36 MXN
|
| Nov. 8, 2016 | 5.0895 |
| Aug. 3, 2016 | 5.0895 |
| May 11, 2016 | 5.0895 |
| Feb. 3, 2016 | 5.0895 |
| ▸2015 |
19.00 MXN
|
| Nov. 4, 2015 | 4.7502 |
| Aug. 5, 2015 | 4.7502 |
| May 6, 2015 | 4.7502 |
| Feb. 4, 2015 | 4.7502 |
| ▸2014 |
17.64 MXN
|
| Nov. 5, 2014 | 4.4109 |
| July 30, 2014 | 4.4109 |
| May 7, 2014 | 4.4109 |
| Feb. 5, 2014 | 4.4109 |
| ▸2013 |
16.29 MXN
|
| Nov. 6, 2013 | 4.0716 |
| July 31, 2013 | 4.0716 |
| May 8, 2013 | 4.0716 |
| Jan. 30, 2013 | 4.0716 |
| ▸2012 |
14.93 MXN
|
| Nov. 7, 2012 | 3.7323 |
| Aug. 1, 2012 | 3.7323 |
| May 9, 2012 | 3.7323 |
| Feb. 1, 2012 | 3.7323 |
| ▸2011 |
13.57 MXN
|
| Nov. 8, 2011 | 3.3930 |
| Aug. 3, 2011 | 3.3930 |
| May 11, 2011 | 3.3930 |
| Feb. 2, 2011 | 3.3930 |
| ▸2010 |
12.21 MXN
|
| Nov. 9, 2010 | 3.0537 |
| Aug. 4, 2010 | 3.0537 |
| May 5, 2010 | 3.0537 |
| Feb. 3, 2010 | 3.0537 |
| ▸2009 |
31.89 MXN
|
| Nov. 4, 2009 | 2.7144 |
| Oct. 13, 2009 | 6.7860 |
| Aug. 5, 2009 | 2.7144 |
| July 13, 2009 | 6.7860 |
| May 6, 2009 | 2.7144 |
| Feb. 13, 2009 | 4.7502 |
| Feb. 4, 2009 | 5.4288 |
| ▸2008 |
38.00 MXN
|
| Nov. 14, 2008 | 4.0716 |
| Nov. 5, 2008 | 5.4288 |
| Aug. 18, 2008 | 4.0716 |
| Aug. 6, 2008 | 5.4288 |
| May 19, 2008 | 4.0716 |
| May 7, 2008 | 5.4288 |
| Feb. 15, 2008 | 4.0716 |
| Feb. 6, 2008 | 5.4288 |
| ▸2007 |
33.25 MXN
|
| Nov. 14, 2007 | 3.4778 |
| Nov. 7, 2007 | 4.9199 |
| Aug. 15, 2007 | 3.4778 |
| Aug. 8, 2007 | 4.9199 |
| May 16, 2007 | 3.4778 |
| May 9, 2007 | 4.9199 |
| Feb. 14, 2007 | 3.1385 |
| Feb. 7, 2007 | 4.9199 |
| ▸2006 |
25.62 MXN
|
| Nov. 15, 2006 | 2.7144 |
| Nov. 8, 2006 | 4.0716 |
| Aug. 16, 2006 | 2.2055 |
| Aug. 9, 2006 | 4.0716 |
| May 17, 2006 | 2.2055 |
| May 10, 2006 | 4.0716 |
| Feb. 15, 2006 | 2.2055 |
| Feb. 8, 2006 | 4.0716 |
| ▸2005 |
20.36 MXN
|
| Nov. 16, 2005 | 1.8662 |
| Nov. 8, 2005 | 3.2234 |
| Aug. 17, 2005 | 1.8662 |
| Aug. 10, 2005 | 3.2234 |
| May 18, 2005 | 1.8662 |
| May 11, 2005 | 3.2234 |
| Feb. 16, 2005 | 1.8662 |
| Feb. 9, 2005 | 3.2234 |
| ▸2004 |
8.65 MXN
|
| Nov. 9, 2004 | 2.8841 |
| Aug. 11, 2004 | 2.8841 |
| May 12, 2004 | 2.8841 |
| Name | Payment Date | Status | Amount |
|---|---|---|---|
| Pfizer Inc. | Jul 24, 2026 | Paid | 7.29495 MXN |
| Pfizer Inc. | May 08, 2026 | Paid | 7.29495 MXN |
| Pfizer Inc. | Jan 23, 2026 | Paid | 7.29495 MXN |
| Pfizer Inc. | Nov 07, 2025 | Paid | 7.29495 MXN |
Community Discussion